Form D · Biotechnology

Lodo Therapeutics Corp

New York, NY · CIK 0001662114

Offering snapshot reported Jan 4, 2017 · SEC filing

Reported sold: $19.9M
Investors reported: 13
Minimum accepted: $0
First sale: Dec 21, 2015

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$3,517,600 → $19,867,600

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jan 4, 2017	Amendment	$19,867,600	$16,350,000vs Jan 4, 2016	13	SEC filing
Jan 4, 2016	Initial	$3,517,600	No comparison	13	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-254438

Source: Form D, filed Jan 4, 2017. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Barbara Dalton	Director
M. Johnston Erwin	Director
Steve Gillis	Director
Thong Le	Director, Executive, Promoter
Joel Marcus	Director
David Mc Elligott	Executive, Promoter
David Pompliano	Executive
Lindsay Rayle	Executive, Promoter
David Schubert	Executive, Promoter
James Sullivan	Director
Misti Ushio	Director
Asish Xavier	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

430 East 29 Th Street, Suite 845
New York, NY, 10016